Single step isolation of sildenafil from commercially available Viagra™ tablets
Open Access
- 1 October 2003
- journal article
- research article
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 15 (5) , 369-372
- https://doi.org/10.1038/sj.ijir.3901040
Abstract
Sildenafil, the active ingredient in Viagra™, ahs been purified from commercially available tablets. The purification, using Sephadex G25 chromatography under conditions of low ionic strength, is simple and inexpensive. Sildenafil purified according to this protocol has been characterized with respect to its IC50 for PDE5, its ultraviolet absorption profile, and by collision-induced dissociation fingerprinting, positive ion nanospray, and MALDI mass spectrometry. Tritated sildenafil (6 Ci/mmol) was prepared commercially using the sildenafil purified by this protocol and was verified to retain the potency of unlabeled sildenafil. This protocol and similar procedures will allow investigators to easily isolate sufficient amounts of sildenafil or other PDE5 inhibitors for conducting biochemical and in vitro studies of drug action.Keywords
This publication has 9 references indexed in Scilit:
- Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial HypertensionCirculation, 2002
- Pharmacological characterization of the ATP-dependent low Km guanosine 3′,5′-cyclic monophosphate (cGMP) transporter in human erythrocytesBiochemical Pharmacology, 2002
- The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafilInternational Journal Of Impotence Research, 2001
- Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.Circulation, 2001
- Allosteric sites of phosphodiesterase‐5 (PDE5)European Journal of Biochemistry, 2001
- Phosphorylation of phosphodiesterase‐5 by cyclic nucleotide‐dependent protein kinase alters its catalytic and allosteric cGMP‐binding activitiesEuropean Journal of Biochemistry, 2000
- Cyclic GMP Phosphodiesterase-5: Target of SildenafilJournal of Biological Chemistry, 1999
- EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMESJournal of Urology, 1998
- Effects of sildenafil, a type‐5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitroBritish Journal of Urology, 1997